ticlopidine Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Millipore ticlopidine
    Mean plasma concentration-time profiles of losartan after oral (9 mg/kg) administration of losartan to rats without (control) and with <t>ticlopidine</t> at doses of 4 and 10 mg/kg. Mean±SD ( n =6). –•–: Control (only losartan 9 mg/kg alone); –○–: Losartan 9 mg/kg+ticlodipine 4 mg/kg; –▾–: Losartan 9 mg/kg+ticlodipine 10 mg/kg.
    Ticlopidine, supplied by Millipore, used in various techniques. Bioz Stars score: 94/100, based on 87 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine/product/Millipore
    Average 94 stars, based on 87 article reviews
    Price from $9.99 to $1999.99
    ticlopidine - by Bioz Stars, 2020-08
    94/100 stars
      Buy from Supplier

    85
    Roche ticlopidine ticlid
    Mean plasma concentration-time profiles of losartan after oral (9 mg/kg) administration of losartan to rats without (control) and with <t>ticlopidine</t> at doses of 4 and 10 mg/kg. Mean±SD ( n =6). –•–: Control (only losartan 9 mg/kg alone); –○–: Losartan 9 mg/kg+ticlodipine 4 mg/kg; –▾–: Losartan 9 mg/kg+ticlodipine 10 mg/kg.
    Ticlopidine Ticlid, supplied by Roche, used in various techniques. Bioz Stars score: 85/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine ticlid/product/Roche
    Average 85 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    ticlopidine ticlid - by Bioz Stars, 2020-08
    85/100 stars
      Buy from Supplier

    90
    Krackeler Scientific ticlopidine
    Mean plasma concentration-time profiles of losartan after oral (9 mg/kg) administration of losartan to rats without (control) and with <t>ticlopidine</t> at doses of 4 and 10 mg/kg. Mean±SD ( n =6). –•–: Control (only losartan 9 mg/kg alone); –○–: Losartan 9 mg/kg+ticlodipine 4 mg/kg; –▾–: Losartan 9 mg/kg+ticlodipine 10 mg/kg.
    Ticlopidine, supplied by Krackeler Scientific, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine/product/Krackeler Scientific
    Average 90 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    ticlopidine - by Bioz Stars, 2020-08
    90/100 stars
      Buy from Supplier

    90
    Sanofi ticlopidine
    The three trials in which patients receiving coronary stents were randomized to receive one or another dosing regimen of <t>ticlopidine</t> or clopidogrel. NS, not significant; MACE, major adverse cardiac events.
    Ticlopidine, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine/product/Sanofi
    Average 90 stars, based on 13 article reviews
    Price from $9.99 to $1999.99
    ticlopidine - by Bioz Stars, 2020-08
    90/100 stars
      Buy from Supplier

    86
    Tocris ticlopidine hydrochloride
    The three trials in which patients receiving coronary stents were randomized to receive one or another dosing regimen of <t>ticlopidine</t> or clopidogrel. NS, not significant; MACE, major adverse cardiac events.
    Ticlopidine Hydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 86/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine hydrochloride/product/Tocris
    Average 86 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    ticlopidine hydrochloride - by Bioz Stars, 2020-08
    86/100 stars
      Buy from Supplier

    91
    Kocak Farma ticlopidine
    The three trials in which patients receiving coronary stents were randomized to receive one or another dosing regimen of <t>ticlopidine</t> or clopidogrel. NS, not significant; MACE, major adverse cardiac events.
    Ticlopidine, supplied by Kocak Farma, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine/product/Kocak Farma
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ticlopidine - by Bioz Stars, 2020-08
    91/100 stars
      Buy from Supplier

    91
    FUJIFILM ticlopidine
    The three trials in which patients receiving coronary stents were randomized to receive one or another dosing regimen of <t>ticlopidine</t> or clopidogrel. NS, not significant; MACE, major adverse cardiac events.
    Ticlopidine, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 91/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine/product/FUJIFILM
    Average 91 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    ticlopidine - by Bioz Stars, 2020-08
    91/100 stars
      Buy from Supplier

    86
    Boehringer Ingelheim ticlopidine trials
    The three trials in which patients receiving coronary stents were randomized to receive one or another dosing regimen of <t>ticlopidine</t> or clopidogrel. NS, not significant; MACE, major adverse cardiac events.
    Ticlopidine Trials, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine trials/product/Boehringer Ingelheim
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ticlopidine trials - by Bioz Stars, 2020-08
    86/100 stars
      Buy from Supplier

    90
    Nichi-Iko ticlopidine hydrochloride
    The three trials in which patients receiving coronary stents were randomized to receive one or another dosing regimen of <t>ticlopidine</t> or clopidogrel. NS, not significant; MACE, major adverse cardiac events.
    Ticlopidine Hydrochloride, supplied by Nichi-Iko, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine hydrochloride/product/Nichi-Iko
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ticlopidine hydrochloride - by Bioz Stars, 2020-08
    90/100 stars
      Buy from Supplier

    85
    Aarti Drugs ticlopidine hydrochloride standard
    Chemical structure of <t>ticlopidine</t> hydrochloride.
    Ticlopidine Hydrochloride Standard, supplied by Aarti Drugs, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ticlopidine hydrochloride standard/product/Aarti Drugs
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ticlopidine hydrochloride standard - by Bioz Stars, 2020-08
    85/100 stars
      Buy from Supplier

    86
    Sanofi sanofi winthrop ticlopidine
    Chemical structure of <t>ticlopidine</t> hydrochloride.
    Sanofi Winthrop Ticlopidine, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sanofi winthrop ticlopidine/product/Sanofi
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sanofi winthrop ticlopidine - by Bioz Stars, 2020-08
    86/100 stars
      Buy from Supplier

    Image Search Results


    Mean plasma concentration-time profiles of losartan after oral (9 mg/kg) administration of losartan to rats without (control) and with ticlopidine at doses of 4 and 10 mg/kg. Mean±SD ( n =6). –•–: Control (only losartan 9 mg/kg alone); –○–: Losartan 9 mg/kg+ticlodipine 4 mg/kg; –▾–: Losartan 9 mg/kg+ticlodipine 10 mg/kg.

    Journal: Acta Pharmacologica Sinica

    Article Title: Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats

    doi: 10.1038/aps.2011.32

    Figure Lengend Snippet: Mean plasma concentration-time profiles of losartan after oral (9 mg/kg) administration of losartan to rats without (control) and with ticlopidine at doses of 4 and 10 mg/kg. Mean±SD ( n =6). –•–: Control (only losartan 9 mg/kg alone); –○–: Losartan 9 mg/kg+ticlodipine 4 mg/kg; –▾–: Losartan 9 mg/kg+ticlodipine 10 mg/kg.

    Article Snippet: Ticlopidine was purchased from Sigma-Aldrich Corporation (St Louis, MO, USA).

    Techniques: Concentration Assay

    Mean plasma concentration-time profiles of EXP-3174 after oral (9 mg/kg) administration of losartan to rats without and with ticlopidine at doses of 4 and 10 mg/kg. Mean±SD ( n =6). –•–: Control (only losartan 9 mg/kg alone); –○–: Losartan 9 mg/kg+ticlodipine 4 mg/kg; –▾–: Losartan 9 mg/kg+ticlodipine 10 mg/kg.

    Journal: Acta Pharmacologica Sinica

    Article Title: Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats

    doi: 10.1038/aps.2011.32

    Figure Lengend Snippet: Mean plasma concentration-time profiles of EXP-3174 after oral (9 mg/kg) administration of losartan to rats without and with ticlopidine at doses of 4 and 10 mg/kg. Mean±SD ( n =6). –•–: Control (only losartan 9 mg/kg alone); –○–: Losartan 9 mg/kg+ticlodipine 4 mg/kg; –▾–: Losartan 9 mg/kg+ticlodipine 10 mg/kg.

    Article Snippet: Ticlopidine was purchased from Sigma-Aldrich Corporation (St Louis, MO, USA).

    Techniques: Concentration Assay

    Mean plasma concentration-time profiles of losartan after iv (3 mg/kg) administration to rats without and with ticlopidine at doses of 4 and 10 mg/kg. Mean±SD ( n =6). –•–: Control (only losartan 3 mg/kg alone); –○–: Losartan 9 mg/kg+ticlodipine 4 mg/kg; –▾–: Losartan 9 mg/kg+ticlodipine 10 mg/kg.

    Journal: Acta Pharmacologica Sinica

    Article Title: Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats

    doi: 10.1038/aps.2011.32

    Figure Lengend Snippet: Mean plasma concentration-time profiles of losartan after iv (3 mg/kg) administration to rats without and with ticlopidine at doses of 4 and 10 mg/kg. Mean±SD ( n =6). –•–: Control (only losartan 3 mg/kg alone); –○–: Losartan 9 mg/kg+ticlodipine 4 mg/kg; –▾–: Losartan 9 mg/kg+ticlodipine 10 mg/kg.

    Article Snippet: Ticlopidine was purchased from Sigma-Aldrich Corporation (St Louis, MO, USA).

    Techniques: Concentration Assay

    Inhibitory effects of ticlopidine on CYP3A4 (A) and 2C9 (B) activity. All experiments were performed in duplicate, and results were expressed as the percent inhibition.

    Journal: Acta Pharmacologica Sinica

    Article Title: Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats

    doi: 10.1038/aps.2011.32

    Figure Lengend Snippet: Inhibitory effects of ticlopidine on CYP3A4 (A) and 2C9 (B) activity. All experiments were performed in duplicate, and results were expressed as the percent inhibition.

    Article Snippet: Ticlopidine was purchased from Sigma-Aldrich Corporation (St Louis, MO, USA).

    Techniques: Activity Assay, Inhibition

    Effect of ticlopidine on the cellular accumulation of rhodamine-123 in MCF-7 and MCF-7/ADR cells. Mean±SD ( n =6).

    Journal: Acta Pharmacologica Sinica

    Article Title: Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats

    doi: 10.1038/aps.2011.32

    Figure Lengend Snippet: Effect of ticlopidine on the cellular accumulation of rhodamine-123 in MCF-7 and MCF-7/ADR cells. Mean±SD ( n =6).

    Article Snippet: Ticlopidine was purchased from Sigma-Aldrich Corporation (St Louis, MO, USA).

    Techniques:

    Reduction of monocyte (U937) adhesion by ticlopidine. HUVECs were incubated with serum-free medium for 12 hours before different concentrations of ticlopidine were added, after 12 hours incubation cells were stimulated with/without TNF- α (10 ng/mL) for another 24 hours. Adhesion of fluorescence-labeled U937 cells was determined by adhesion assay. Data are expressed as the mean ± SEM of five individual experiments. Significantly different versus TNF-treated alone * P

    Journal: Journal of Biomedicine and Biotechnology

    Article Title: Reduction of Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels by Ticlopidine in TNF-α Stimulated Human Umbilical Vein Endothelial Cells

    doi: 10.1155/2009/917837

    Figure Lengend Snippet: Reduction of monocyte (U937) adhesion by ticlopidine. HUVECs were incubated with serum-free medium for 12 hours before different concentrations of ticlopidine were added, after 12 hours incubation cells were stimulated with/without TNF- α (10 ng/mL) for another 24 hours. Adhesion of fluorescence-labeled U937 cells was determined by adhesion assay. Data are expressed as the mean ± SEM of five individual experiments. Significantly different versus TNF-treated alone * P

    Article Snippet: Materials Ticlopidine was purchased from Sigma (St. Louis, MO), and U937 cells from Culture Collection and Research Center CCRC No. 68002 (Hsinchu, Taiwan).

    Techniques: Incubation, Fluorescence, Labeling, Cell Adhesion Assay

    Reduction of U937 cells chemotaxis by ticlopidine. HUVECs were incubated at the upper wells of the transwell plates until confluency, then different concentrations of ticlopidine were added. After 30 minutes of incubation, cells were stimulated with/without TNF- α (10 ng/mL). U937 cells were added to the upper chamber wells and incubated for 1.5 hours. The cells chemotastic to the lower wells were counted. Data are expressed as the mean ± SEM of three individual experiments. Significantly different versus TNF-treated alone * P

    Journal: Journal of Biomedicine and Biotechnology

    Article Title: Reduction of Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels by Ticlopidine in TNF-α Stimulated Human Umbilical Vein Endothelial Cells

    doi: 10.1155/2009/917837

    Figure Lengend Snippet: Reduction of U937 cells chemotaxis by ticlopidine. HUVECs were incubated at the upper wells of the transwell plates until confluency, then different concentrations of ticlopidine were added. After 30 minutes of incubation, cells were stimulated with/without TNF- α (10 ng/mL). U937 cells were added to the upper chamber wells and incubated for 1.5 hours. The cells chemotastic to the lower wells were counted. Data are expressed as the mean ± SEM of three individual experiments. Significantly different versus TNF-treated alone * P

    Article Snippet: Materials Ticlopidine was purchased from Sigma (St. Louis, MO), and U937 cells from Culture Collection and Research Center CCRC No. 68002 (Hsinchu, Taiwan).

    Techniques: Chemotaxis Assay, Incubation

    Reduction of IL-8 mRNA and protein levels by ticlopidine in HUVECs. HUVECs were incubated with serum-free medium for 12 hours before different concentrations of ticlopidine were added, after 12 hours incubation cells were stimulated with/without TNF- α (10 ng/mL) for another 24 hours. (a) Total RNA was extracted and analyzed by RT-PCR. Lane 1, without TNF- α ; lane 2, TNF- α (10 ng/mL) alone; lane 3, TNF- α + ticlopidine (0.1 μ g/mL); lane 4 TNF- α + ticlopidine (30 μ g/mL); M denotes molecular size marker. The lower panel is β -actin as the internal control. Results are representative one of three independent experiments. (b) Relative amount of IL-8 mRNA level was determined by quantitative real-time RT-PCR. (c) Culture supernatants were analyzed by ELISA. Data are expressed as the mean ± SEM of duplicate wells and are representative of six individual experiments. Significantly different versus TNF-treated alone* P

    Journal: Journal of Biomedicine and Biotechnology

    Article Title: Reduction of Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels by Ticlopidine in TNF-α Stimulated Human Umbilical Vein Endothelial Cells

    doi: 10.1155/2009/917837

    Figure Lengend Snippet: Reduction of IL-8 mRNA and protein levels by ticlopidine in HUVECs. HUVECs were incubated with serum-free medium for 12 hours before different concentrations of ticlopidine were added, after 12 hours incubation cells were stimulated with/without TNF- α (10 ng/mL) for another 24 hours. (a) Total RNA was extracted and analyzed by RT-PCR. Lane 1, without TNF- α ; lane 2, TNF- α (10 ng/mL) alone; lane 3, TNF- α + ticlopidine (0.1 μ g/mL); lane 4 TNF- α + ticlopidine (30 μ g/mL); M denotes molecular size marker. The lower panel is β -actin as the internal control. Results are representative one of three independent experiments. (b) Relative amount of IL-8 mRNA level was determined by quantitative real-time RT-PCR. (c) Culture supernatants were analyzed by ELISA. Data are expressed as the mean ± SEM of duplicate wells and are representative of six individual experiments. Significantly different versus TNF-treated alone* P

    Article Snippet: Materials Ticlopidine was purchased from Sigma (St. Louis, MO), and U937 cells from Culture Collection and Research Center CCRC No. 68002 (Hsinchu, Taiwan).

    Techniques: Incubation, Reverse Transcription Polymerase Chain Reaction, Marker, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

    Reduction of VCAM-1 mRNA and protein levels by ticlopidine in HUVECs. HUVECs were incubated with serum-free medium for 12 hours before different concentrations of ticlopidine were added, after 12 hours incubation cells were stimulated with/without TNF- α (10 ng/mL) for another 24 hours. (a) Relative amount of VCAM-1 mRNA level was determined by quantitative real-time RT-PCR. (b) Culture supernatants were analyzed by ELISA. Data are expressed as the mean ± SEM of duplicate wells and are representative of three individual experiments. Significantly different versus TNF-treated alone * P

    Journal: Journal of Biomedicine and Biotechnology

    Article Title: Reduction of Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels by Ticlopidine in TNF-α Stimulated Human Umbilical Vein Endothelial Cells

    doi: 10.1155/2009/917837

    Figure Lengend Snippet: Reduction of VCAM-1 mRNA and protein levels by ticlopidine in HUVECs. HUVECs were incubated with serum-free medium for 12 hours before different concentrations of ticlopidine were added, after 12 hours incubation cells were stimulated with/without TNF- α (10 ng/mL) for another 24 hours. (a) Relative amount of VCAM-1 mRNA level was determined by quantitative real-time RT-PCR. (b) Culture supernatants were analyzed by ELISA. Data are expressed as the mean ± SEM of duplicate wells and are representative of three individual experiments. Significantly different versus TNF-treated alone * P

    Article Snippet: Materials Ticlopidine was purchased from Sigma (St. Louis, MO), and U937 cells from Culture Collection and Research Center CCRC No. 68002 (Hsinchu, Taiwan).

    Techniques: Incubation, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

    Reduction of MCP-1 mRNA and protein levels by ticlopidine in HUVECs. HUVECs were incubated with serum-free medium for 12 hours before different concentrations of ticlopidine were added, after 12 hours incubation cells were stimulated with/without TNF- α (10 ng/mL) for another 24 hours. (a) Cell growth was analyzed by MTT. Results are mean ± SEM ( n = 3). (b) Total RNA was extracted and analyzed by RT-PCR. Lane 1, without TNF- α ; lane 2, TNF- α (10 ng/mL) alone; lane 3, TNF- α + ticlopidine (0.1 μ g/mL); lane 4 TNF- α + ticlopidine (30 μ g/mL); M denotes molecular size marker. The lower panel is β -actin as internal control. Results are representative of one of three independent experiments. (c) Relative amount of MCP-1 mRNA level was determined by quantitative real-time RT-PCR. (d) Culture supernatants were analyzed by ELISA. Data are expressed as the mean ± SEM of duplicate wells and are representative of five individual experiments. Significantly different versus TNF-treated alone * P

    Journal: Journal of Biomedicine and Biotechnology

    Article Title: Reduction of Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels by Ticlopidine in TNF-α Stimulated Human Umbilical Vein Endothelial Cells

    doi: 10.1155/2009/917837

    Figure Lengend Snippet: Reduction of MCP-1 mRNA and protein levels by ticlopidine in HUVECs. HUVECs were incubated with serum-free medium for 12 hours before different concentrations of ticlopidine were added, after 12 hours incubation cells were stimulated with/without TNF- α (10 ng/mL) for another 24 hours. (a) Cell growth was analyzed by MTT. Results are mean ± SEM ( n = 3). (b) Total RNA was extracted and analyzed by RT-PCR. Lane 1, without TNF- α ; lane 2, TNF- α (10 ng/mL) alone; lane 3, TNF- α + ticlopidine (0.1 μ g/mL); lane 4 TNF- α + ticlopidine (30 μ g/mL); M denotes molecular size marker. The lower panel is β -actin as internal control. Results are representative of one of three independent experiments. (c) Relative amount of MCP-1 mRNA level was determined by quantitative real-time RT-PCR. (d) Culture supernatants were analyzed by ELISA. Data are expressed as the mean ± SEM of duplicate wells and are representative of five individual experiments. Significantly different versus TNF-treated alone * P

    Article Snippet: Materials Ticlopidine was purchased from Sigma (St. Louis, MO), and U937 cells from Culture Collection and Research Center CCRC No. 68002 (Hsinchu, Taiwan).

    Techniques: Incubation, MTT Assay, Reverse Transcription Polymerase Chain Reaction, Marker, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

    Ticlopidine has no effect on NF-kB activation. HUVECs were incubated with different concentrations of ticlopidine, and 100 μ g/mL of aspirin was added as the control. Cells were stimulated with/without TNF- α (10 ng/mL) for 30 minutes, nuclear and cytosolic proteins were collected. Briefly, the nuclear protein extracts were collected, and western blots were performed using anti-NFkB p65 and anti-B23 Ab (a). Cytosolic protein extracts were collected, and western blots were performed using anti-Ik-B- α and α -tubulin Ab (b). Lane 1, without TNF- α ; lane 2, TNF- α (10 ng/mL) alone; lane 3, TNF- α + aspirin (100 μ g/mL); lane 4, TNF- α + ticlopidine (1 μ g/mL); lane 5, TNF- α + ticlopidine (10 μ g/mL); lane 6, TNF- α + ticlopidine (30 μ g/mL). Results are representative of one of three independent experiments.

    Journal: Journal of Biomedicine and Biotechnology

    Article Title: Reduction of Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels by Ticlopidine in TNF-α Stimulated Human Umbilical Vein Endothelial Cells

    doi: 10.1155/2009/917837

    Figure Lengend Snippet: Ticlopidine has no effect on NF-kB activation. HUVECs were incubated with different concentrations of ticlopidine, and 100 μ g/mL of aspirin was added as the control. Cells were stimulated with/without TNF- α (10 ng/mL) for 30 minutes, nuclear and cytosolic proteins were collected. Briefly, the nuclear protein extracts were collected, and western blots were performed using anti-NFkB p65 and anti-B23 Ab (a). Cytosolic protein extracts were collected, and western blots were performed using anti-Ik-B- α and α -tubulin Ab (b). Lane 1, without TNF- α ; lane 2, TNF- α (10 ng/mL) alone; lane 3, TNF- α + aspirin (100 μ g/mL); lane 4, TNF- α + ticlopidine (1 μ g/mL); lane 5, TNF- α + ticlopidine (10 μ g/mL); lane 6, TNF- α + ticlopidine (30 μ g/mL). Results are representative of one of three independent experiments.

    Article Snippet: Materials Ticlopidine was purchased from Sigma (St. Louis, MO), and U937 cells from Culture Collection and Research Center CCRC No. 68002 (Hsinchu, Taiwan).

    Techniques: Activation Assay, Incubation, Western Blot

    The three trials in which patients receiving coronary stents were randomized to receive one or another dosing regimen of ticlopidine or clopidogrel. NS, not significant; MACE, major adverse cardiac events.

    Journal: Current Controlled Trials in Cardiovascular Medicine

    Article Title: Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?

    doi: 10.1186/cvm-1-2-083

    Figure Lengend Snippet: The three trials in which patients receiving coronary stents were randomized to receive one or another dosing regimen of ticlopidine or clopidogrel. NS, not significant; MACE, major adverse cardiac events.

    Article Snippet: Sanofi manufactures both ticlopidine and clopidogrel, and co-markets clopidogrel with Bristol-Meyer Squibb in the United States.

    Techniques:

    Results of the Ticlid or Plavix Post-Stents (TOPPS) Trial. MI, myocardial infarction; TVR, target vessel revascularization.

    Journal: Current Controlled Trials in Cardiovascular Medicine

    Article Title: Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?

    doi: 10.1186/cvm-1-2-083

    Figure Lengend Snippet: Results of the Ticlid or Plavix Post-Stents (TOPPS) Trial. MI, myocardial infarction; TVR, target vessel revascularization.

    Article Snippet: Sanofi manufactures both ticlopidine and clopidogrel, and co-markets clopidogrel with Bristol-Meyer Squibb in the United States.

    Techniques:

    Data from seven registries in which the clinical outcome of patients receiving coronary stents treated with clopidogrel was compared with that of patients treated with ticlopidine. NS, not significant; MACE, major adverse cardiac events.

    Journal: Current Controlled Trials in Cardiovascular Medicine

    Article Title: Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?

    doi: 10.1186/cvm-1-2-083

    Figure Lengend Snippet: Data from seven registries in which the clinical outcome of patients receiving coronary stents treated with clopidogrel was compared with that of patients treated with ticlopidine. NS, not significant; MACE, major adverse cardiac events.

    Article Snippet: Sanofi manufactures both ticlopidine and clopidogrel, and co-markets clopidogrel with Bristol-Meyer Squibb in the United States.

    Techniques:

    Chemical structure of ticlopidine hydrochloride.

    Journal: Saudi Pharmaceutical Journal : SPJ

    Article Title: Development and validation of a stability indicating UPLC method for determination of ticlopidine hydrochloride in its tablet formulation

    doi: 10.1016/j.jsps.2011.03.005

    Figure Lengend Snippet: Chemical structure of ticlopidine hydrochloride.

    Article Snippet: Ticlopidine hydrochloride standard was provided by Aarti Drugs Ltd., Boisar (India).

    Techniques: